×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Multi-stakeholder considerations for sustainable clinical trials – why is it important and what action is needed?
Session Chair(s)
![Daniel Reed, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Daniel Reed, PhD
Senior Regulatory Intelligence Director
AstraZeneca, United Kingdom
Claudia Percivalle, PhD, MSc
Regulatory Affairs Director
AstraZeneca, United Kingdom
Multi-stakeholder considerations for sustainable clinical trials – why is it important and what action is needed?
Have an account?